Px Wire April-June 2014, Vol. 7, No. 2

Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reviews the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in HIV-negative people and also explores progress in implementing oral PrEP in the nearly 24 months since the US Food and Drug Administration approved daily oral TDF/FTC (Truvada) as PrEP.